Hassan Elsayegh

Dr. Hassan Elsayegh

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 November 2025 in Healthcare
Verified
Journal Article
Open access
PDF file
ASAmani Nabil Shafik
Amani Nabil Shafik
VFVeronia Fawzy Fahim
Veronia Fawzy Fahim
FIFady Fady Iskander
Fady Fady Iskander
HEHassan Elsayegh
Hassan Elsayegh
HSHani Serag
Hani Serag
Hanaa SallamHanaa Sallam
Hanaa Sallam
This review provides a comprehensive overview of the complex and dynamic bacterial composition of the human gastrointestinal (GI) microbiota and explores its integral role in the microbiome–gut–brain axis. It discusses the physiological and molecular pathways through which the gut microbiota communicates with the central nervous system, highlighting key barriers that can impede effective signaling along this axis. The review also delves into the influence of microbiota on brain health, including cognitive function, mood regulation, and neuroinflammation. It considers how disruptions in this system—known as dysbiosis—can contribute to metabolic and neurological dysfunction. The central focus of the article is the role of the commonly prescribed antidiabetic drug metformin, not only in regulating glucose metabolism but also in its emerging potential to beneficially modulate the gut microbiome. By doing so, metformin may indirectly support improved brain health. Ultimately, the article seeks to inform both healthcare practitioners and patients about the promising therapeutic implications of microbiome-targeted strategies, particularly metformin, in promoting cognitive and neurological well-being.

29 September 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
ASAmani Nabil Shafik
Amani Nabil Shafik
VFVeronia Fawzy Fahim
Veronia Fawzy Fahim
FIFady Fady Iskander
Fady Fady Iskander
HEHassan Elsayegh
Hassan Elsayegh
HSHani Serag
Hani Serag
Hanaa SallamHanaa Sallam
Hanaa Sallam
Objectives: This review provides a comprehensive overview of the complex and dynamic bacterial composition of the human gastrointestinal (GI) microbiota and explores its integral role in the microbiome-gut-brain axis. Methods: It discusses the physiological and molecular pathways through which the gut microbiota communicates with the central nervous system, highlighting key barriers that can impede effective signaling along this axis. The review also delves into the influence of the microbiota on brain health, including cognitive function, mood regulation, and neuroinflammation, and considers how disruptions in this system—known as dysbiosis—can contribute to metabolic and neurological dysfunction. Results: A central focus of the article is the role of the commonly prescribed antidiabetic drug Metformin, not only in regulating glucose metabolism but also in its emerging potential to beneficially modulate the gut microbiome. By doing so, Metformin may indirectly support improved brain health. Conclusions: Ultimately, the article seeks to inform both healthcare practitioners and patients about the promising therapeutic implications of microbiome-targeted strategies, particularly the use of Metformin, in promoting cognitive and neurological well-being.

3 March 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
VFVeronia Fawzy Fahim
Veronia Fawzy Fahim
GAGehad Sayed Ahmed
Gehad Sayed Ahmed
FIFady Fady Iskander
Fady Fady Iskander
HEHassan Elsayegh
Hassan Elsayegh
AEAhmed Eltawel
Ahmed Eltawel
ASAmani Nabil Shafik
Amani Nabil Shafik
Background/Objectives: Delirium is an acute state of confusion associated with impaired consciousness and a decline in cognitive function. Delirium has significant clinical importance due to its substantial impact on morbidity and mortality. The primary objective of this systematic review is to assess Dexmedetomidine’s potential efficacy for delirium in critically ill and elderly patients, addressing a significant need in this high-risk population, and to evaluate its safety as a secondary objective. Methods: A systematic review (2018–2024) searched PubMed, Embase, and Cochrane for English-language studies on dexmedetomidine and delirium in older intensive care unit (ICU) patients. Dual reviewers independently screened, extracted data, and resolved disagreements. Eligible randamized control trials (RCTs) and observational studies were assessed using Risk of Bias 2 ( RoB-2) and Risk Of Bias In Non-randomized Studies - of Interventions (ROBINS-I) tools. Results: Dexmedetomidine emerges as a promising drug because of its unique pharmacological profile, which provides sedation without modulating gamma-aminobutyric acid (GABA) receptors, potentially lowering the risk of delirium. Its additional analgesic, anti-inflammatory, and organ-protective characteristics could provide broader clinical benefits in the ICU. However, the aged population’s heightened susceptibility to Dexmedetomidine’s hemodynamic effects may limit some of its potential benefits. Conclusions: Although existing research suggests short-term neuroprotective effects, these effects do not always translate into better long-term survival. As a result, further large-scale, well-designed randomized controlled trials are needed to determine the optimal use of Dexmedetomidine in this population and to understand its overall impact on morbidity and mortality in the ICU.